Average Co-Inventor Count = 8.90
ph-index = 14
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Forma Therapeutics, Inc. (50 from 125 patents)
2. Amgen Inc. (10 from 1,970 patents)
3. Valo Health, Inc. (8 from 29 patents)
4. Valo Early Discovery, Inc. (5 from 15 patents)
5. H. Lee Moffitt Cancer Center and Research Institute, Inc. (1 from 290 patents)
73 patents:
1. 12264137 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
2. 12049466 - Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
3. 11919839 - Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
4. 11891365 - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
5. 11814386 - Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
6. 11535618 - Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
7. 11535607 - Isoindolines as HDAC inhibitors
8. 11345672 - Methods using HDAC11 inhibitors
9. 11299484 - Inhibiting fatty acid synthase (FASN)
10. 11279681 - 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
11. 11274084 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
12. 11274085 - 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
13. 11267805 - Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone
14. 11247987 - Inhibiting ubiquitin specific peptidase 30
15. 11111229 - Tetrahydroquinoline compositions as BET bromodomain inhibitors